PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31782100-0	2020	OSU-6162, a Sigma1R Ligand in Low Doses, Can Further Increase the Effects of Cocaine Self-Administration on Accumbal D2R Heteroreceptor Complexes.	OSU 6162	0-8	sigma non-opioid intracellular receptor 1	Rattus norvegicus	12-19
31782100-2	2020	It therefore becomes of interest to test if the monoamine stabilizer (-) OSU-6162 (OSU-6162) with a nanomolar affinity for the Sigma1R can acutely modulate in low doses the effects of cocaine self-administration.	OSU 6162	73-81	sigma non-opioid intracellular receptor 1	Rattus norvegicus	127-134
31782100-2	2020	It therefore becomes of interest to test if the monoamine stabilizer (-) OSU-6162 (OSU-6162) with a nanomolar affinity for the Sigma1R can acutely modulate in low doses the effects of cocaine self-administration.	OSU 6162	83-91	sigma non-opioid intracellular receptor 1	Rattus norvegicus	127-134
31782100-5	2020	In contrast, in maintenance of cocaine self-administration, the proximity ligation assay performed on brains from rats pretreated with OSU-6162 showed highly significant increases in the density of the D2R-Sigma1R heteroreceptor complexes in the shell of the nucleus accumbens versus OSU-6162 induced increases in this region of yoked saline rats.	OSU 6162	135-143	sigma non-opioid intracellular receptor 1	Rattus norvegicus	206-213
31782100-5	2020	In contrast, in maintenance of cocaine self-administration, the proximity ligation assay performed on brains from rats pretreated with OSU-6162 showed highly significant increases in the density of the D2R-Sigma1R heteroreceptor complexes in the shell of the nucleus accumbens versus OSU-6162 induced increases in this region of yoked saline rats.	OSU 6162	284-292	sigma non-opioid intracellular receptor 1	Rattus norvegicus	206-213
31782100-6	2020	In cocaine self-administration, highly significant increases were also induced by OSU-6162 in the A2AR-D2R heteroreceptor complexes in the nucleus accumbens shell versus vehicle-treated rats.	OSU 6162	82-90	adenosine A2a receptor	Rattus norvegicus	98-102
31782100-7	2020	Furthermore, ex vivo, the A2AR agonist CGS21680 (100 nM) produced a marked and significant increase of the D2R Ki high values in the OSU-6162-treated versus vehicle-treated rats under maintenance of cocaine self-administration.	OSU 6162	133-141	adenosine A2a receptor	Rattus norvegicus	26-30
31782100-9	2020	The current results indicate that OSU-6162 via its high affinity for the Sigma1R may increase the number of accumbal shell D2R-Sigma1R and A2AR-D2R heteroreceptor complexes associated with further increases in the antagonistic A2AR-D2R interactions in cocaine self-administration.	OSU 6162	34-42	sigma non-opioid intracellular receptor 1	Rattus norvegicus	73-80
31782100-9	2020	The current results indicate that OSU-6162 via its high affinity for the Sigma1R may increase the number of accumbal shell D2R-Sigma1R and A2AR-D2R heteroreceptor complexes associated with further increases in the antagonistic A2AR-D2R interactions in cocaine self-administration.	OSU 6162	34-42	sigma non-opioid intracellular receptor 1	Rattus norvegicus	127-134
31782100-9	2020	The current results indicate that OSU-6162 via its high affinity for the Sigma1R may increase the number of accumbal shell D2R-Sigma1R and A2AR-D2R heteroreceptor complexes associated with further increases in the antagonistic A2AR-D2R interactions in cocaine self-administration.	OSU 6162	34-42	adenosine A2a receptor	Rattus norvegicus	139-143
31782100-9	2020	The current results indicate that OSU-6162 via its high affinity for the Sigma1R may increase the number of accumbal shell D2R-Sigma1R and A2AR-D2R heteroreceptor complexes associated with further increases in the antagonistic A2AR-D2R interactions in cocaine self-administration.	OSU 6162	34-42	adenosine A2a receptor	Rattus norvegicus	227-231
20804495-0	2010	Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.	OSU 6162	78-85	dopamine receptor D2	Homo sapiens	103-123
22560595-0	2012	The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins.	OSU 6162	29-40	huntingtin	Mus musculus	116-126
22560595-5	2012	We investigated the effects of (-)-OSU6162 on huntingtin knocked-in striatal neurons in culture.	OSU 6162	31-42	huntingtin	Mus musculus	46-56
22560595-12	2012	(-)-OSU6162 increases the intracellular levels of BDNF and Bcl2/Bax and decreases those of p-ERK/ERK and CHIP in Q111 cells.	OSU 6162	4-11	brain derived neurotrophic factor	Mus musculus	50-54
22560595-12	2012	(-)-OSU6162 increases the intracellular levels of BDNF and Bcl2/Bax and decreases those of p-ERK/ERK and CHIP in Q111 cells.	OSU 6162	4-11	B cell leukemia/lymphoma 2	Mus musculus	59-63
22560595-12	2012	(-)-OSU6162 increases the intracellular levels of BDNF and Bcl2/Bax and decreases those of p-ERK/ERK and CHIP in Q111 cells.	OSU 6162	4-11	BCL2-associated X protein	Mus musculus	64-67
22560595-12	2012	(-)-OSU6162 increases the intracellular levels of BDNF and Bcl2/Bax and decreases those of p-ERK/ERK and CHIP in Q111 cells.	OSU 6162	4-11	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	91-96
22560595-12	2012	(-)-OSU6162 increases the intracellular levels of BDNF and Bcl2/Bax and decreases those of p-ERK/ERK and CHIP in Q111 cells.	OSU 6162	4-11	mitogen-activated protein kinase 1	Mus musculus	93-96
21866391-1	2011	In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.	OSU 6162	23-34	5-hydroxytryptamine receptor 2A	Rattus norvegicus	92-98
21866391-1	2011	In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.	OSU 6162	39-50	5-hydroxytryptamine receptor 2A	Rattus norvegicus	92-98
21866391-6	2011	Both enantiomers of OSU6162 were medium intrinsic activity partial agonists at 5-HT2A receptors and low intrinsic activity partial agonists at D2 receptors.	OSU 6162	20-27	5-hydroxytryptamine receptor 2A	Rattus norvegicus	79-85
21866391-7	2011	(+)-OSU6162 had higher efficacy at 5-HT2A receptors, which correlated with its greater stimulatory activity in vivo, but (-)-OSU6162 had higher potency at D2 receptors, which correlated with its greater inhibitory activity in vivo.	OSU 6162	0-11	5-hydroxytryptamine receptor 2A	Rattus norvegicus	35-41
21874578-1	2011	In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.	OSU 6162	48-59	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	79-85
21874578-1	2011	In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.	OSU 6162	64-75	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	79-85
21874578-13	2011	Overall, these results indicate that the dual effects on behavior of (-)- and (+)-OSU6162 are mediated through D2 and 5-HT2A receptors, consistent with their in vitro functional selectivity profiles (see Burstein et al., accompanying paper).	OSU 6162	78-89	5-hydroxytryptamine (serotonin) receptor 2A	Mus musculus	118-124
21533991-0	2011	Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.	OSU 6162	36-51	prolactin	Rattus norvegicus	65-74
21533991-6	2011	We find that OSU6162 and ACR16 both stimulate prolactin secretion in drug-naive rats with OSU6162 being considerably more potent and efficacious.	OSU 6162	13-20	prolactin	Rattus norvegicus	46-55
19919834-0	2010	The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties.	OSU 6162	53-64	dopamine receptor D2	Homo sapiens	73-95
19919834-5	2010	In contrast to the high-affinity typical antipsychotics haloperidol and raclopride, the dopaminergic stabilizers ACR16 and (-)-OSU6162 both displayed fast dopamine D(2) receptor dissociation properties, a feature that has previously been suggested as a contributing factor to antipsychotic atypicality and attributed mainly to low receptor affinity.	OSU 6162	123-134	dopamine receptor D2	Homo sapiens	155-177
11312565-2	2001	We studied the effects of coadministration of (-)-OSU6162 with l-DOPA on the regulation of striatal preproenkephalin (PPE) and prodynorphin (PDyn) mRNA expression in the primate brain by in situ hybridization histochemistry.	OSU 6162	46-57	proenkephalin-B	Callithrix jacchus	141-145
12433806-6	2002	quinidine, a CYP2D6-specific inhibitor, inhibited (-)-OSU6162 N-depropylation, whereas other p450 enzyme-specific substrates/inhibitors did not significantly inhibit this activity; 3).	OSU 6162	50-61	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	13-19
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-69
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	79-85
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	95-102
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	104-110
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	112-118
12433806-8	2002	In addition, the selectivity of (-)-OSU6162 to inhibit six human p450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP2D6 and CYP3A4) was evaluated using an in vitro inhibition screen.	OSU 6162	32-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129
12433806-9	2002	Of the enzymes examined, only the activity of CYP2D6 was inhibited by coincubation with (-)-OSU6162.	OSU 6162	88-99	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
12433806-10	2002	Thus, it is concluded that (-)-OSU6162 is metabolized by several p450 enzymes and that CYP2D6 accounts for the majority of the observed p450 N-depropylase activity in vitro.	OSU 6162	27-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	65-69
12433806-10	2002	Thus, it is concluded that (-)-OSU6162 is metabolized by several p450 enzymes and that CYP2D6 accounts for the majority of the observed p450 N-depropylase activity in vitro.	OSU 6162	27-38	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	87-93
12433806-10	2002	Thus, it is concluded that (-)-OSU6162 is metabolized by several p450 enzymes and that CYP2D6 accounts for the majority of the observed p450 N-depropylase activity in vitro.	OSU 6162	27-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	136-140
17157291-3	2007	We found that (-)-OSU6162 had a dissociation constant of 35 nM at the functional high-affinity site of the dopamine D2 receptor, stimulated the incorporation of [35S]-GTP-gamma-S above 100 nM, and inhibited the incorporating action of 1 microM dopamine with an inhibitory dissociation constant, Ki, of 27 nM, all being properties of a dopamine partial agonist.	OSU 6162	14-25	dopamine receptor D2	Homo sapiens	107-127
12433806-1	2002	(S,S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride [(-)-OSU6162] is a weak dopamine D2 receptor modulator that possesses potential for the treatment of levodopa (L-DOPA)-induced dyskinesias in patients with Parkinson"s disease.	OSU 6162	69-80	dopamine receptor D2	Homo sapiens	92-112
12433806-3	2002	Kinetics evidence is presented that the N-depropylation of (-)-OSU6162 in human hepatic microsomes is mediated by multiple cytochrome p450 (p450) enzymes, in particular CYP2D6.	OSU 6162	59-70	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	134-138
12433806-3	2002	Kinetics evidence is presented that the N-depropylation of (-)-OSU6162 in human hepatic microsomes is mediated by multiple cytochrome p450 (p450) enzymes, in particular CYP2D6.	OSU 6162	59-70	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	140-144
12433806-3	2002	Kinetics evidence is presented that the N-depropylation of (-)-OSU6162 in human hepatic microsomes is mediated by multiple cytochrome p450 (p450) enzymes, in particular CYP2D6.	OSU 6162	59-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	169-175
12433806-5	2002	incubations of (-)-OSU6162 (5 micro M) with hepatic microsomes from a panel of human donors showed that (-)-OSU6162 N-depropylase activity correlated well with CYP2D6-catalyzed dextromethorphan O-demethylase activity but not with other p450 enzyme-specific activities; 2).	OSU 6162	15-26	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	160-166
12433806-5	2002	incubations of (-)-OSU6162 (5 micro M) with hepatic microsomes from a panel of human donors showed that (-)-OSU6162 N-depropylase activity correlated well with CYP2D6-catalyzed dextromethorphan O-demethylase activity but not with other p450 enzyme-specific activities; 2).	OSU 6162	15-26	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	236-240
11166288-1	2001	(S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine ((-)-OSU6162) is a phenylpiperidine derivative which exhibits low affinity to the dopamine D2 receptor in vitro.	OSU 6162	57-68	dopamine receptor D2	Homo sapiens	138-158